1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-156521
    αvβ1 integrin-IN-2
    Inhibitor
    αvβ1 integrin-IN-2 (compound 32) is a potent inhibitor of integrins ανβ1 and α5β1 with IC50s of 0.9 nM,and 33 nM,respectively. αvβ1 integrin-IN-2 also inhibits other integrins with ,,IC50s of 380 nM (ανβ3),280 nM (ανβ5),230 nM (ανβ6),87 nM (ανβ8),respectively,in SPRA assay.
    αvβ1 integrin-IN-2
  • HY-122230
    UR-3216
    Inhibitor
    UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research.
    UR-3216
  • HY-P5767
    Fibrinogen γ-chain (117-133)
    Inhibitor
    Fibrinogen γ-chain (117-133) is a selective intercellular adhesion molecule-1 (ICAM-1) inhibitor (IC50≈20-40 μg/mL). Fibrinogen γ-chain (117-133) blocks fibrinogen-mediated monocyte-endothelial adhesion. Fibrinogen γ-chain (117-133) is promising for research of thrombo-inflammatory diseases (e.g., atherosclerosis, organ transplant rejection).
    Fibrinogen γ-chain (117-133)
  • HY-12159
    MK-0668
    Antagonist
    MK-0668 is an amino acid-based, potent antagonist of unactivated VLA-4, with an IC50) of 0.13 nM in human whole blood. And MK-0668 exhibits IC50s of 0.19 nM in dogs, 0.21 nM in rhesus monkeys, and 0.4 nM in rats.
    MK-0668
  • HY-17369BS
    Tirofiban-d9
    Antagonist
    Tirofiban-d9 is deuterium labeled Tirofiban.
    Tirofiban-d<sub>9</sub>
  • HY-10315
    Elarofiban
    Antagonist
    Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research.
    Elarofiban
  • HY-P10783
    BGC0222
    Modulator
    BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors.
    BGC0222
  • HY-122192
    ICAM-1988
    Antagonist
    ICAM-1988 is a small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonist that disrupts the LFA-1/ICAM-1 interaction and has anti-inflammatory activity.
    ICAM-1988
  • HY-P991644
    IMGN388 Antibody
    Inhibitor
    IMGN388 Antibody is an Integrin targeting humanized monoclonal antibody. IMGN388 Antibody can be used for synthesis of ADC SGN-PDL1V (HY-171821).
    IMGN388 Antibody
  • HY-P10988
    LVTX-8
    LVTX-8 is a peptide toxin, exacted from Lycosa vittata. LVTX-8 has potent anticancer and and anti-metastasis activities towards lung cancer with strong cytotoxicity. LVTX-8 significantly induces apoptosis and inhibits the proliferation, invasion and migration of lung cancer cells through P53 hypoxia pathways and integrin signaling. LVTX-8 significantly inhibits the tumor growth and metastasis in A549/H460 xenograft mice model.
    LVTX-8
  • HY-161095
    iRGD-CPT
    iRGD-CPT is a conjugate of iRGD and camptothecin that is covalently coupled through a heterobifunctional linker. iRGD-CPT has anticancer activity in vitroandin vivo. iRGD-CPT can be used for the study of colon cancer.
    iRGD-CPT
  • HY-136699
    Excisanin A
    Inhibitor
    Excisanin A is a potent anticancer agent. Excisanin A inhibits cell proliferation, migration, adhesion and invasion. Excisanin A decreases the expression of MMP-2, MMP-9, p-FAK, p-Src, integrin β1 protein. Excisanin A has the potential for the research of breast cancer.
    Excisanin A
  • HY-P990871
    Anti-CD11a/LFA-1α Antibody (R7-1)
    Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human CD11a/LFA-1α. Anti-CD11a/LFA-1α Antibody (R7-1) can neutralize LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. Anti-CD11a/LFA-1α Antibody (R7-1) can be used for the research of inflammation.
    Anti-CD11a/LFA-1α Antibody (R7-1)
  • HY-125123
    Euchrestaflavanone A
    Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis.
    Euchrestaflavanone A
  • HY-P6009
    Cys-αvβ6-BP
    Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide.
    Cys-αvβ6-BP
  • HY-161730
    αvβ1 integrin-IN-3
    Inhibitor
    αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect.
    αvβ1 integrin-IN-3
  • HY-P10677
    HB-3-20
    Degrader
    HB-3-20 leads to degradation of the cell surface integrin αVβ5. Transglutaminase 2 (TG2) has specificity for HB-3-20 (kcat/KM=0.16 μM-1min-1).
    HB-3-20
  • HY-10304A
    Orbofiban acetate
    98.13%
    Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
    Orbofiban acetate
  • HY-124040
    BI-1950
    Inhibitor
    BI-1950, a chemical probe, is a highly potent lymphocyte function associated antigen-1 (LFA-1) inhibitor. LFA-1 is an essential component in normal immune system function and a target for agent discovery.
    BI-1950
  • HY-P2633A
    Dentonin TFA
    Dentonin TFA (AC-100 TFA) is a synthetic fragment derived from MEPE. Dentonin TFA enhances osteogenesis by promoting osteoprogenitor adhesion and facilitates immature adherent cells survival. Dentonin TFA has no significant effect to mature osteoblasts. Dentonin TFA can be used for the research of phosphate homeostasis and bone metabolism.
    Dentonin TFA
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.